NEW YORK (TheStreet) -- Quintiles Transnational Holdings (Q) is the world's largest provider of biopharmaceutical development and commercial outsourcing services. The stock is up 30% year to date and has outperformed the iShares Nasdaq Biotechnology ETF (IBB) - Get Report by 10% in that period.
Jim Cramer interviewed Tom Pike, the CEO of Quintiles, on Mad Money on Tuesday. Pike described the company as "a simple story in a very complex industry."
Quintiles' technical picture confirms Pike's view. Simply put, the stock price keeps moving from the lower left of the chart to the upper right.
The stock has been trending higher above a rising 200-day moving average and an uptrend line drawn off the lows since October 2014. Last month it pulled back to the trend line but immediately began consolidating in a rising triangle pattern, just below the 50-day moving average. Last week the stock closed above the 50-day average and horizontal pattern resistance, and there has been follow-through price action so far this week.
Moving average convergence/divergence made a bullish crossover at the beginning of the month, and the relative strength index has crossed above its 21-period signal average and centerline. These indications reflect positive price momentum and confirm the shift in trend from pullback to recovery. Chaikin money flow, a 21-period average of accumulation/distribution, turned into positive territory and is reflecting renewed buying interest in the stock.
Quintiles is a long candidate at its current level with a trailing percentage stop under the 50-day moving average.
Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.